This document is an excerpt from the EUR-Lex website
Document 52023M11300
Prior notification of a concentration (Case M.11300 – CINVEN / SYNLAB) – Candidate case for simplified procedure
Prior notification of a concentration (Case M.11300 – CINVEN / SYNLAB) – Candidate case for simplified procedure
Prior notification of a concentration (Case M.11300 – CINVEN / SYNLAB) – Candidate case for simplified procedure
PUB/2023/1585
OJ C, C/2023/702, 6.11.2023, ELI: http://data.europa.eu/eli/C/2023/702/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
Official Journal |
EN Series C |
|
C/2023/702 |
6.11.2023 |
Prior notification of a concentration
(Case M.11300 – CINVEN / SYNLAB)
Candidate case for simplified procedure
(Text with EEA relevance)
(C/2023/702)
1.
On 25 October 2023, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).This notification concerns the following undertakings:
|
— |
Cinven Capital Management (V) General Partner Limited (‘Cinven’, Guernsey), |
|
— |
SYNLAB AG (‘SYNLAB’, Germany). |
Cinven will acquire within the meaning of Article 3(1)(b) of the Merger Regulation indirect sole control of the whole of SYNLAB.
The concentration is accomplished by way of purchase of shares following a public offer announced on 29 September 2023.
2.
The business activities of the undertakings concerned are the following:|
— |
Cinven, a private equity firm engaged in the provision of investment management and investment advisory services to a number of investment funds. The companies in Cinven’s portfolio of investments are active in a variety of sectors across a range of jurisdictions, |
|
— |
SYNLAB provides medical diagnostic services and special diagnostics, primarily in the sector of human medicine in Europe, Africa, Asia and South America. |
3.
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.Pursuant to the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004 on the control of concentrations between undertakings (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.
4.
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.11300 – CINVEN / SYNLAB
Observations can be sent to the Commission by email or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
|
Postal address: |
|
European Commission |
|
Directorate-General for Competition |
|
Merger Registry |
|
1049 Bruxelles/Brussel |
|
BELGIQUE/BELGIË |
(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).
ELI: http://data.europa.eu/eli/C/2023/702/oj
ISSN 1977-091X (electronic edition)